COMBINATION OF A 17-ALPHA-HYDROXYLASE (C17,20-LYASE) INHIBITOR AND A SPECIFIC PI-3K INHIBITOR FOR TREATING A TUMOR DISEASE
First Claim
1. A combination comprising (a) a phosphatidylinositol 3-kinase inhibitor selected from the group consisting of the compound of formula (I),
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor selected from the group consisting of a compound of formula (I) or a compound of formula (II), or pharmaceutically acceptable salt thereof, (b) a 17α-Hydroxylase/C17,20-lyase inhibitor (CYP17 inhibitor), specifically abiraterone acetate and 1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for the treatment of a tumor disease; a pharmaceutical composition comprising such combination; use of such combination for the treatment of a tumor disease; a commercial package or product comprising such combination; and to a method of treating a patient having a tumor disease comprising administration of said combination to a patient in need thereof.
-
Citations
20 Claims
- 1. A combination comprising (a) a phosphatidylinositol 3-kinase inhibitor selected from the group consisting of the compound of formula (I),
-
5-6. -6. (canceled)
-
10. A method of treating a patient having a tumor disease which comprises administering to a subject in need thereof a combination comprising a phosphatidylinositol 3-kinase inhibitor selected from the group consisting of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile (COMPOUND A), 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (COMPOUND B), and 5-(2,6-di-morpholin-4-yl-pyrimidin-4-vl)-4-trifluoromethyl-pyridin-2-ylamine (COMPOUND C) or a pharmaceutically acceptable salt thereof and (b) a 17α
- -Hydroxylase/C17,20-lyase inhibitor or pharmaceutically acceptable salt thereof in a quantity which is jointly therapeutically effective against said tumor disease.
- View Dependent Claims (12, 14, 15, 16, 18, 20)
-
11. (canceled)
-
13. (canceled)
-
17. (canceled)
-
19. (canceled)
Specification